Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting.

Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting. Clin Cancer Res. 2020 Jan 30;: Authors: Yaeger R, Solit DB Abstract KRAS G12C inhibitors have shown promise in KRAS G12C mutant lung cancer but intrinsic and acquired resistance are common. Co-treatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition. PMID: 32001483 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research